Reports

Ideas That Generate Results

Global Vaccine Market Outlook 2020

Global Vaccine Market Outlook 2020

Format :  Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : May, 2014| No. of Pages : 135

Share |
 
Please make your selection :
Electronic Access - Single User License
US$ 1500.00
CD-ROM Mail Delivery
US$ 1700.00
Hard Copy Mail Delivery
US$ 1700.00
Electronic Access - Multi-User License
US$ 2000.00

List of Figures:

Figure 3-1: Global - Vaccine Market (Billion US$), 2013-2020
Figure 4-1: Global - Causes of Deaths in Children (<5 Years) among Low-income Countries (%), 2011
Figure 4-2: Global - Pneumococcal Vaccine Market (Billion US$), 2013-2020
Figure 4-3: Global - Influenza Vaccine Market (Billion US$), 2013-2020
Figure 4-4: Global - Cancer Vaccine Market (Billion US$), 2013-2020
Figure 4-5: Global - Polio Vaccine Market (Billion US$), 2013-2020
Figure 4-6: Global - Varicella Vaccine Market (Billion US$), 2013-2020
Figure 4-7: Global - Rotavirus Vaccine Market (Billion US$), 2013-2020
Figure 4-8: Global - Meningococcal Vaccine Market (Billion US$), 2013-2020
Figure 4-9: Global - Number of Diphtheria Incidences by Region (2009 & 2010)
Figure 4-10: Global - Number of nTetanus Incidences by Region (2009 & 2010)
Figure 4-11: Global - Number of tTetanus Incidences by Region (2009 & 2010)
Figure 4-12: Global - Number of Pertussis Incidences by Region (2009 & 2010)
Figure 4-13: Global - DTP Vaccine Market (Billion US$), 2013-2020
Figure 4-14: Global - Hepatitis Vaccine Market (Billion US$), 2013-2020
Figure 4-15: Global - Number of Measles Incidences by Region (2009 & 2010)
Figure 4-16: Global - Number of Mumps Incidences by Region (‘000), 2009 & 2010
Figure 4-17: Global - Number of Rubella Incidences by Region (2009 & 2010)
Figure 4-18: Global - MMR Vaccine Market (Million US$), 2013-2020
Figure 4-19: Global - Japanese Encephalitis Market (Million US$), 2013-2020
Figure 4-20: Global - Sources for Funding in HIV Vaccine R&D (%), 2011
Figure 5-1: Global - Vaccine Market by Region (%), 2013
Figure 5-2: Global - Vaccine Market by Region (%), 2020
Figure 5-3: US - Vaccine Market (Billion US$), 2013-2020
Figure 5-4: Europe - Vaccine Market (Billion US$), 2013-2020
Figure 5-5: Japan - Vaccine Market (Billion US$), 2013-2020
Figure 5-6: China - Vaccine Market (Billion US$), 2013-2020
Figure 5-7: India - Share of Domestic Consumption and Exports in Vaccine Market (2013)
Figure 5-8: India - Vaccine Market (Billion US$), 2013-2020
Figure 5-9: Brazil - Vaccine Market (Billion US$), 2013-2020
Figure 7-1: Global - Share of Key Players in Vaccine Market (2013)
Figure 7-2: GSK - Revenue Breakup by Business Segment (%), 2013
Figure 7-3: GSK - Vaccine Revenue Breakup by Product (%), 2013
Figure 7-4: Sanofi-Pasteur - Revenue Breakup by Business Segment (%), 2013
Figure 7-5: Sanofi-Pasteur - Vaccine Revenue Breakup by Product (%), 2013
Figure 7-6: Pfizer - Revenue Breakup by Business Segment (%), 2013
Figure 7-7: Pfizer - Revenue Breakup by Biopharmaceuticals (%), 2013
Figure 7-8: Merck - Revenue Breakup by Business Segment (%), 2013
Figure 7-9: Merck - Pharmaceutical Division Revenue by Segment (%), 2013
Figure 7-10: Novartis - Revenue Breakup by Business Segment (%), 2013
Figure 7-11: AstraZeneca - Revenue Breakup by Therapy Area (%), 2013
Figure 7-12: Baxter International - Revenue Breakup by Business Segment (%), 2013
Figure 7-13: BioCSL - Revenue Breakup by Business Segment (%), 2013
Figure 7-14: Takeda Pharmaceutical - Revenue Breakup by Business Segment (%), 2013
Figure 7-15: Crucell - Revenue Breakup by Vaccine Type (%), 2010

List of Tables:

Table 4-1: Pneumococcal Vaccine Market - Key Players and Vaccines
Table 4-2: Key Pneumococcal Vaccines in Pipeline
Table 4-3: Influenza Vaccine Market - Key Players and Vaccines
Table 4-4: Key Influenza Vaccines in Pipeline
Table 4-5: Global - Cancer Statistics in More Developed and Less Developed Regions (2008)
Table 4-6: Cancer Vaccine Market - Key Players and Vaccines
Table 4-7: Key Cancer Vaccines in Pipeline
Table 4-8: Polio Vaccine Market - Key Players and Vaccines
Table 4-9: Key Polio Vaccines in Pipeline
Table 4-10: Varicella Vaccine Market - Key Players and Vaccines
Table 4-11: Rotavirus Vaccine Market - Key Players and Vaccines
Table 4-12: Key Rotavirus Vaccines in Pipeline
Table 4-13: Meningococcal Vaccine Market - Key Players and Vaccines
Table 4-14: Key Meningococcal Vaccines in Pipeline
Table 4-15: DTP Vaccine Market - Key Players and Vaccines
Table 4-16: Key DTP Vaccines in Pipeline
Table 4-17: Hepatitis Vaccine Market - Key Players and Vaccines
Table 4-18: Key Hepatitis Vaccines in Pipeline
Table 4-19: MMR Vaccine Market - Key Players and Vaccines
Table 4-20: Key MMR Vaccines in Pipeline
Table 4-21: Japanese Encephalitis Vaccine Market - Key Players and Vaccines
Table 4-22: Key Japanese Encephalitis Vaccines in Pipeline
Table 4-23: Tuberculosis Vaccine Market - Key Players and Vaccines
Table 4-24: Key Tuberculosis Vaccines in Pipeline
Table 4-25: Key Malaria Vaccines in Pipeline
Table 4-26: Rabies Vaccine Market - Key Players and Vaccines
Table 4-27: Key Rabies Vaccines in Pipeline
Table 4-28: Typhoid Vaccine Market - Key Players and Vaccines
Table 4-29: Key Typhoid Vaccines in Pipeline
Table 4-30: Global - Number of HIV/AIDS Patients by Region (2009)
Table 4-31: Key HIV Vaccines in Pipeline
Table 5-1: China - Vaccine Classification
Table 6-1: Vaccine Pipeline Analysis
Table 7-1: GSK - Vaccines Portfolio
Table 7-2: GSK - Vaccines in Pipeline
Table 7-3: GSK - Strengths and Weaknesses
Table 7-4: Sanofi-Pasteur - Vaccines Portfolio
Table 7-5: Sanofi-Pasteur - Vaccines in Pipeline
Table 7-6: Sanofi-Pasteur - Strengths and Weaknesses
Table 7-7: Pfizer - Vaccines Portfolio
Table 7-8: Pfizer - Vaccines in Pipeline
Table 7-9: Pfizer - Strengths and Weaknesses
Table 7-10: Merck - Vaccines Portfolio
Table 7-11: Merck - Vaccines in Pipeline
Table 7-12: Merck - Strengths and Weaknesses
Table 7-13: Novartis - Vaccines Portfolio
Table 7-14: Novartis - Vaccines in Pipeline
Table 7-15: Novartis - Strengths and Weaknesses
Table 7-16: Emergent Biosolutions - Vaccines Portfolio
Table 7-17: Emergent Biosolutions - Vaccines in Pipeline
Table 7-18: Emergent Biosolutions - Strengths and Weaknesses
Table 7-19: AstraZeneca - Vaccines Portfolio
Table 7-20: AstraZeneca - Vaccines in Pipeline
Table 7-21: AstraZeneca - Strengths and Weaknesses
Table 7-22: Baxter International - Vaccines Portfolio
Table 7-23: Baxter International - Vaccines in Pipeline
Table 7-24: Baxter International - Strengths and Weaknesses
Table 7-25: BioCSL - Vaccines Portfolio
Table 7-26: BioCSL - Strengths and Weaknesses
Table 7-27: Dendreon Corporation - Vaccines Portfolio
Table 7-28: Dendreon Corporation - Vaccines in Pipeline
Table 7-29: Dendreon Corporation - Strengths and Weaknesses
Table 7-30: Takeda Pharmaceutical - Vaccines Portfolio
Table 7-31: Takeda Pharmaceutical - Vaccines in Pipeline
Table 7-32: Takeda Pharmaceutical - Strengths and Weaknesses
Table 7-33: Crucell - Vaccines Portfolio
Table 7-34: Crucell - Vaccines in Pipeline
Table 7-35: Crucell - Strengths and Weaknesses

Not able to find data you are looking for? Ask our Research Analyst.

media citation

get in touch

Please fill-in the information below.